Imagine learning that your newborn baby has a devastating disease that could rob them of their ability to walk, breathe independently, or even survive past the age of two. This is the heartbreaking reality singer Jesy Nelson is facing after her twin daughters were diagnosed with Spinal Muscular Atrophy (SMA), a rare and severe muscle-wasting condition. But here's where it gets even more heartbreaking: this diagnosis could have been caught earlier, potentially saving families from months of agonizing uncertainty and giving children a better chance at treatment. Now, Nelson is on a mission to ensure no other parent endures this preventable pain.
In an emotional Instagram post, the former Little Mix star revealed her seven-month-old daughters, Ocean Jade and Story Monroe, were diagnosed with SMA after months of grueling appointments and tests. She described SMA as a relentless disease that attacks every muscle in the body, from limbs to vital functions like breathing and swallowing. Without timely treatment, the prognosis is grim: most children with SMA don’t live past their second birthday. While her daughters have received treatment, doctors have warned they may never walk or regain full neck strength, leaving them permanently disabled.
And this is the part most people miss: SMA can be detected through a simple blood test, yet it’s not currently included in the NHS’s newborn screening program, which checks for 10 other conditions. Nelson is now campaigning to change this, launching a petition to add SMA to the newborn heel prick test. “I’m going to fight as much as I can to make this part of the newborn screening,” she declared, her determination palpable. The issue is under review, and Nelson has vowed to keep her followers updated.
Her advocacy has already sparked a wave of support, with Health Secretary Wes Streeting acknowledging her efforts and pledging to explore not just SMA screening but also the broader use of genomic medicine. Scotland is leading the way, set to introduce routine SMA screening for newborns this spring, while the UK National Screening Committee considers a nationwide rollout. Meanwhile, treatments like the gene therapy drug Zolgensma offer hope, but timing is critical—irreversible damage can occur before diagnosis.
Here’s the controversial part: While the NHS has introduced three new SMA treatments since 2019, critics argue that screening delays are costing precious time. Is it fair for families to endure months of uncertainty when a simple test could provide answers? And why isn’t SMA already part of routine newborn screening, given its severity and the availability of treatments? These questions are fueling a growing debate, with Nelson’s campaign adding urgency to the conversation.
As Nelson herself put it, “I’m overwhelmed by the support, but this isn’t just about my daughters—it’s about every family facing this diagnosis.” Her fight is a reminder that early detection can change lives, and her courage in sharing her story is inspiring action. But the question remains: Will the system move fast enough to save the next child? What do you think? Should SMA screening be prioritized, or are there other factors to consider? Let’s keep the conversation going—because every moment counts.
